



MEDIA ADVISORY

May 10, 2015

Sequella, Inc. Selected to Present at Cavendish Global Health Impact Forum

Forum uniquely brings together leading family offices and their foundations seeking impact investment, grant-giving, and philanthropy opportunities within health and life sciences

La Jolla, CA — Sequella, Inc., a clinical-stage company developing novel antibiotics for drug-resistant infections, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place May 10th to May 14th in La Jolla, California. The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission, the Forum showcases presentations and panel discussions by leading research institutions, accomplished healthcare delivery professionals, health-policy experts and private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment. A unique gathering of leading family offices, Cavendish Impact Forums are hosted by leading institutions around the world and take place three times each year. The next Forum is being co-hosted by the community of La Jolla, California including The University of California San Diego, The J. Craig Venter Institute, The Scripps Research Institute, The Sanford-Burnham Medical Research Institute, The Sanford Consortium for Regenerative Medicine, and The Institute of the Americas.

Michael Moffat, Cavendish co-founder and Chief Executive Officer explains, "The theme of our La Jolla, California Forum is a *'Celebration of Philanthropy, Impact Investing and Innovation that is Changing the World.'* With the help of our expert advisors, we conducted a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence. The quality and originality of Sequella's research and clinical development in global health, particularly in drug-resistant infections that disproportionately affect disadvantaged populations around the world, positions them to make a major contribution to the treatment of global scourges that kill millions of people yearly."

"We are honored to be selected to present at this unique event, and it is further recognition of our innovative approaches to develop novel antibiotics that can improve treatment of infections that afflict populations around the world today," said Carol Nancy, CEO. "We welcome the chance to interact with many of world's most accomplished scientists, thought-leaders, and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world."

Cavendish Global consists of leading family offices and foundations from around the world with combined assets of over \$190 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish Global Health Impact Forum provides family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for family offices to champion and share information on projects and organizations, which they are passionate about with other family offices from around the world.

About Sequella, Inc.

Sequella is a privately-held clinical stage anti-infectives company focused on commercializing novel treatments for antibiotic-resistant infectious diseases. The company has been in operation for 17 years and has drugs in Phase 2 clinical trials for gastritis (*Helicobacter pylori*) and TB (Phase 2) and in IND-directed preclinical development for *Clostridium difficile* infections. Sequella leverages its global influence, R&D platforms, and infectious disease expertise to proactively address emerging health threats. Through focused execution, clear commercialization pathways, and strategic partnerships, Sequella intends to commercialize a broad product portfolio designed to treat global health threats with significant market opportunity. www.sequella.com

Forward-Looking Statement

This press release contains forward-looking statements that are subject to risks and uncertainties, and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Sequella disclaims any intent or obligation to update forward-looking statements, except as required by law.

Sequella Media Contacts: Alicia Moran
AM Media and Marketing
Telephone: 410-991-7027
aliciamoranmedia@gmail.com

or

Carol A. Nancy, Ph.D.
CEO
Telephone: 301-762-7776
Email: carolnacy@sequella.com

About Cavendish Global

(<http://cavendishglobal.com>)

Cavendish Global provides family offices and their foundations with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the innovative resources required to help develop and implement their individual pro-social impact investment and philanthropy programs within health and the life sciences. Cavendish Global provides family offices with a number of innovative resources, which includes Cavendish Impact Forums. A unique gathering of leading family offices, Cavendish Impact Forums take place three times each year; the next Forum is being co-hosted at leading research institutions of the community of La Jolla, California including The University of California San Diego, The J. Craig Venter Institute, The Scripps Research Institute, The Sanford-Burnham Medical Research Institute, The Sanford Consortium for Regenerative Medicine, and The Institute of the Americas.

For more information: <http://cavendishglobal.com>

For Further Information Contact:

Alex Charlton

President, Cavendish Global

alex.charlton@cavendishglobal.com

Tel: +1-917-576-1435